Associate Professor, Nephrology, BIRDEM General Hospital & Ibrahim Medical college,
Dhaka, Bangladesh
Joined July 2020
- Tweets247
- Following494
- Followers156
- Likes131
Dr. Md. Mostarshid Billah retweeted
SGLT2i’s seem to be in the drinking water these days. Euglycemic DKA says hello now and then. This short, three-page editorial helps us manage this family of medications when these patients are in our ICU. 🎩 tip to the authors.
eddyjoemd.com/foamed
Dr. Md. Mostarshid Billah retweeted
SGLT2 inhibitor (SGLT2i) Cold 🥶 Map: Indications for SGLT2i in CKD/ Albuminuria/ Type 2 Diabetes (T2D)/ Heart Failure (HFrEF, HFmrEF, HFpEF) from @ISNkidneycare @goKDIGO @RPANephrology @ASPCardio
#Nephpearls #Cardiorenal
👉 theisn.org/initiatives/toolk…
Dr. Md. Mostarshid Billah retweeted
Prophylaxis in Glomerular Disease by Dr. Corey Cavanaugh
Total live participants: 110
From 48 countries
Watch the session here 👉 my.glomcon.org
#GlomCon
Dr. Md. Mostarshid Billah retweeted
FSGS is not one disease!
Looking forward to this talk by @fervenzafernan1 on how to dissect and approach the diagnosis and management of the various causes of FSGS 👇
Join GlomCon this Sunday
Focal and Segmental Glomerulosclerosis: A Need for Better Phenotyping Patients by Dr. Fernando Fervenza
ID: 875 5077 1266
Passcode 202122
sign up 👉🏻 my.glomcon.org
#GlomCon
Dr. Md. Mostarshid Billah retweeted
This study shows chlorthalidone improved BP control among patients with advanced CKD independently of baseline urinary sodium, aldosterone, weight loss, or changes in the renin-angiotensin system bit.ly/CJASN0484
ALT Directed acyclic graph of proposed causal mediation pathways.
Dr. Md. Mostarshid Billah retweeted
Nonlupus full house nephropathy is a rare, complex entity. This study supports that SLE and nonlupus full house nephropathy are distinct clinical entities, with comparable outcomes bit.ly/CJASN0438
@AKronbichler
ALT Visual Abstract for the article titled "Nonlupus Full House Nephropathy"
Dr. Md. Mostarshid Billah retweeted
‼️ Pls join for an amazing talk on Amyloidosis facts and myths by Dr Leung
➡️August 28 2024, 4:30-5:30 EST
@MSK_Neph @SheronLatcha
#OncoNephrology
Dr. Md. Mostarshid Billah retweeted
🔥IV iron and hypophosphatemia
🎯Mostly seen with ferric carboxylmaltose FCM
How 🤔-FCM ➡️ FGF23 rise➡️ phosphate excretion 🆙
🙏Fortunately CKD pts at low risk➡️impaired GFR limits PO4 excretion in urine
🔥Suspect hypoPO4👆if a pt post IV iron➡️c/o myalgia/fatigue/bone pain
onlinelibrary.wiley.com/doi/…
Dr. Md. Mostarshid Billah retweeted
🔔New @goKDIGO guideline for lupus nephritis was published so fast after the last one!
📰What is the news, then?
💬 Let's discuss more on #NephJC chats on February 6 and 7
nephjc.com/news/kdigo-lupus2…
Dr. Md. Mostarshid Billah retweeted
💥ISOT- RENAL TRANSPLANT PATHOLOGY CERTIFICATE COURSE
Get ready for 3️⃣rd webinar
Topic: Chronic Active T cell mediated Rejection
By Dr Radhika Krishna Patil
📆 17/01/24
🕰️ 06:30 PM
#ISOTTxPath
Dr. Md. Mostarshid Billah retweeted
Top Nephrology Stories for 2023 from @NephJC #Nephpearls
#VisualGraphic by @priti899
👉🏼 nephjc.com/news/2024/1/15/to… – at Maywood, IL
Dr. Md. Mostarshid Billah retweeted
🔥🫘Do you recommend low protein diet for your CKD patient (non dialysis Stage 3-5)
🤷♀️Difficult to decide
👍Theoretically Low protein diet(0.6-0.8 gm/Kg/day) -reduce intraglomerular pressure-⬇️GFR decline
👎😳Concerns of protein energy wasting and inadequate protein intake
📌Read this interesting write up in @NEJM
nejm.org/doi/full/10.1056/NE…
Dr. Md. Mostarshid Billah retweeted
🚨 Updated guidelines alert! The UKKA’s latest update on Treatment of Acute Hyperkalaemia in Adults brings crucial changes. From IV calcium salt rates to novel potassium binder use for moderate & severe cases, these changes are reshaping care standards.
➡️ bit.ly/41K6eIG
Dr. Md. Mostarshid Billah retweeted
The KDIGO 2024 Clinical Practice Guideline for the Management of #lupusnephritis is finally out! @ISNkidneycare @goKDIGO kidney-international.org/art…
Dr. Md. Mostarshid Billah retweeted
Clinical Practice Guideline for the Management of Lupus Nephritis ca. 2024 from @goKDIGO #Nephpearls
📌 Immunosuppressive treatment for patients with Class I or Class II lupus nephritis
📌 Recommended approach for initial therapy of active Class III/IV lupus nephritis
📌 Recommended options of maintenance therapy for Class III and Class IV lupus nephritis
📌 Management of patients with pure Class V lupus nephritis
👉 kidney-international.org/art… – at Riverside, IL
Dr. Md. Mostarshid Billah retweeted
IKDRC Ahmedabad 2023
Total kidney Transplants 353
Deceased donors 155 (44%)
Living related donor 147
Swap 43( of total 521 swap)
Other than near related donors 8
44% deceased donors where national average is around 15%
22% of living donors are swap
year 2000-2023
Total kidney transplants 6614
Living donors 5301
Deceased donors 1313
Swap 521 HIGHEST in Asia
Majority (95%)of transplants are FREE under Government schemes such as PMJAY Ayushmann Bharat
HAPPY NEW YEAR
@NottoIndia @DghsIndia @IndiaSoTx
Dr. Md. Mostarshid Billah retweeted
So excited to share our @AJKDonline Core Curriculum with co-authors @danielwross4 & O'Neill is now online, a case-based approach showcasing how to incorporate US into clinical decision-making across the spectrum of kidney disease! Free, full text here: authors.elsevier.com/a/1iGED… Thank you @melhoenig for the invitation!🙏 @EmoryNephrology @ASDINNews @JasonCobbMD @Nephro_Sparks @ssfarouk @aishaikh @kdjhaveri @edgarvlermamd @NephroP @nephrothaniel @ArgaizR @VelezNephHepato @nephrorock @nephrosingh @nephrosharma